$ADPT

Adaptive Biotechnologies (ADPT) reported stronger-than-expected Q3 2026 results, raised its outlook, and reaffirmed profitability expectations. The company's stock has surged 65.73% year-to-date, closing at $26.92 on October 26, 2026. Alger Small Cap Growth Fund highlighted ADPT's diagnostic tools, including clonoSEQ, which was referenced in clinical guidelines for monitoring multiple myeloma.

RUBINSTEIN JULIE (President and COO) sold 35,643 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $25.18 ($24.38–$26.30, $0.90M total) across 6 trades over 2026-10-22 to 2026-10-26 under a Rule 10b5-1 trading plan.

RUBINSTEIN JULIE (President and COO) sold 35,643 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $24.66 ($24.05–$25.57, $0.88M total) across 5 trades over 2026-10-19 to 2026-10-21 under a Rule 10b5-1 trading plan.

RUBINSTEIN JULIE (President and COO) sold 35,643 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $25.18 ($24.21–$25.82, $0.90M total) across 5 trades over 2026-10-14 to 2026-10-16 under a Rule 10b5-1 trading plan.

RUBINSTEIN JULIE (President and COO) sold 35,643 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $25.81 ($25.35–$26.41, $0.92M total) across 4 trades over 2026-10-09 to 2026-10-13 under a Rule 10b5-1 trading plan.

Adaptive Biotechnologies (ADPT) shares fell despite Morgan Stanley's $27 price target, citing limited upside. Micron (MU) dropped 4% on competition fears, but Cavenagh Research upgraded it to Strong Buy with a $2,577 target, citing contractual pricing protections and strong financials.

U.S. analyst updates on October 12th, 2026, show a cautious outlook with more price-target reductions than increases. Financials, insurance, and real estate saw conservative valuations, while tech sentiment was mixed. Energy received stronger support, and healthcare saw positive coverage.

Adaptive Biotechnologies' average stock price target increased from $28.31 to $28.94 by 8 analysts, with a range of $21 to $35. This suggests a 9% upside from the Oct. 9 closing price. The consensus rating remains 'Buy' with 8 Buys, 1 Hold, and 0 Sells.

RUBINSTEIN JULIE (President and COO) sold 35,643 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $26.60 ($25.66–$30.53, $0.95M total) across 6 trades over 2026-10-06 to 2026-10-08 under a Rule 10b5-1 trading plan.

Adaptive Biotechnologies' COO Julie Rubinstein sold $1.01m in stock and exercised options for $432,706 in October 2026. ADPT stock is near its 52-week high at $29.84, up 106% year-over-year. Q2 results showed a wider-than-expected loss but revenue beat estimates. Analysts raised price targets, with BTIG and Goldman Sachs at $34 and $35 respectively, while Guggenheim set a $25 target.